The HEADACHE Act directs the Secretary of Health and Human Services to stand up a National Headache Disorders Initiative (NHDI) to coordinate federal research, clinical care, workforce development, and public awareness for migraine and other headache disorders. The bill mandates cross‑agency coordination, standardized data sharing (including EHRs and registries), and an annual report to Congress that must include an updated national plan and recommendations on diagnostics, access, and federal spending.
To advise the Secretary the bill creates an Advisory Council composed of enumerated federal agencies and twelve non‑federal members (patients, caregivers, clinicians, researchers, and advocacy representatives). The law sets meeting requirements, requires integration with existing pain programs, explicitly calls out disparities and vulnerable populations, and sunsets five years after enactment.
The statute prescribes program duties but does not itself appropriate funds.
At a Glance
What It Does
The bill requires HHS to implement a coordinated federal initiative (NHDI) that prioritizes basic and clinical headache research, workforce expansion, improved diagnostic and care pathways, stigma reduction, and international coordination. It creates an Advisory Council with specified federal agency seats plus 12 external members (patients, clinicians, researchers, advocates), mandates standardized data sharing across agencies and with non‑federal sources, and requires an annual report and national plan to Congress.
Who It Affects
Directly affected stakeholders include HHS and other federal agencies with health data (NIH, FDA, CDC, VA, DOD, CMS, IHS, AHRQ, ARPA‑H, PCORI), clinical headache specialists and front‑line providers, patient advocacy organizations, health systems that hold EHRs and registries, and researchers focused on pain and headache disorders. Medicare and other federally funded programs appear in scope via required evaluations and budget reviews.
Why It Matters
The bill elevates headache disorders — a high‑burden, historically underfunded set of conditions — to a cross‑agency priority, demands interoperable data and an updated national plan, and embeds patient representation in advisory policymaking. For compliance officers and health program managers, it creates new expectations around data sharing, program evaluation, and interagency budgeting that could change federal funding priorities and clinical practice guidance.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The HEADACHE Act tasks the Secretary of Health and Human Services with creating a National Headache Disorders Initiative (NHDI). The NHDI must be a cross‑cutting program: HHS is to increase the clinical and research workforce focused on headache care, prioritize fundamental and translational research to speed and lower the cost of diagnosis, develop new therapeutics, and create care pathways that account for comorbidities.
The initiative must also mount public awareness work to reduce stigma and coordinate with existing federal pain efforts such as the HEAL Initiative and the NIH Pain Consortium.
The bill establishes an Advisory Council to advise the Secretary. Membership is explicitly enumerated: federal seats for agencies such as NIH, FDA, CDC, CMS, VA, DOD, IHS, AHRQ, ARPA‑H, PCORI, and the National Center for Complementary and Integrative Health; plus 12 outside members appointed by the Secretary, including patient advocates (one with migraine and one with a non‑migraine disorder), a caregiver of a child or adolescent with headache, clinicians whose practices are predominantly headache patients (with minimum roles specified across physician, advanced practice provider, behavioral health, orofacial pain, front‑line provider), a researcher, and an advocacy organization representative.
The Council must meet at least quarterly for two years and hold an annual research meeting.On data, the statute requires federal agencies with headache‑related data to share it with HHS at the Secretary’s request and asks for standardization and integration with non‑federal sources (EHRs, registries, surveys). HHS must use that data to produce an annual report to Congress that evaluates federally funded research and care programs, documents disparities, recommends priority actions (including reducing financial burdens on Medicare and others), and issues an annually updated national plan.
The law is explicit that the program should address vulnerable populations (children, pregnant women, older adults) and newer diagnostic categories such as headache secondary to long COVID.Finally, the Act contains a hard sunset — it ceases to be effective five years after enactment. The statute specifies duties and structures but does not itself appropriate funds; implementation will therefore depend on agency budget decisions or later appropriations.
The Five Things You Need to Know
The bill requires HHS to implement a National Headache Disorders Initiative (NHDI) that coordinates research, workforce expansion, clinical care pathways, stigma reduction, and international collaboration for headache disorders.
Section 4 creates an Advisory Council with named federal agency seats (NIH, FDA, CDC, CMS, IHS, VA, DOD, AHRQ, ARPA‑H, PCORI, NCCIH, Department of Education and others) plus 12 non‑federal appointees including specified patient, caregiver, clinician, and researcher roles.
Non‑federal clinician appointees must include providers whose practices are predominantly headache patients and specific roles (MD/DO, advanced practice provider, behavioral health specialist, orofacial pain specialist, front‑line provider, and a headache researcher).
The law obligates federal agencies to share standardized headache‑related data with HHS (including EHRs, patient registries, and population surveys) at the Secretary’s request and requires an annual HHS report to Congress with an updated national plan and disparity data.
The Act imposes a five‑year sunset and does not itself authorize appropriations, making implementation contingent on agency resources and future funding decisions.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title and scope
Gives the Act its name (HEADACHE Act) and frames the statute’s purpose: to direct HHS to establish and manage a national initiative, an advisory council, data sharing, and reporting. Practically, this anchors the program in HHS but leaves room for broad interagency work; the short title itself creates no obligations beyond those in later sections.
Definitions — what counts as a headache disorder
Defines "headache disorder" broadly to cover primary and secondary conditions where headache is a principal symptom and lists examples (migraine, cluster, tension‑type, CSF leak, intracranial hypertension, new daily persistent headache, long COVID‑related headache, orofacial pain, post‑traumatic headache). By specifying vulnerable populations (children, pregnant women, older adults), the definition widens the initiative’s clinical and research remit and signals explicit attention to equity in data collection and care pathways.
National Headache Disorders Initiative (NHDI) — duties and priorities
Requires HHS to establish an NHDI that (a) builds a comprehensive program addressing medical, societal, and economic impacts, (b) expands the clinical and research workforce, (c) coordinates with existing federal pain programs (HEAL, NIH Pain Consortium, Centers of Excellence in Pain Education, etc.), (d) aligns federal resources with disease burden, and (e) prioritizes fundamental, translational, and clinical research to improve diagnosis and treatment. Operationally this creates a multi‑pronged mandate: program design, priority setting, interagency coordination, and specific research and care pathway deliverables that HHS must oversee and update.
Advisory Council — composition, meetings, and role
Establishes an advisory body with both federal and non‑federal members. Federal representation is carved out by agency, which institutionalizes cross‑agency participation. The 12 external seats are tightly specified to ensure patient voices, caregiver perspectives, clinicians with high headache caseloads, behavioral and orofacial specialists, front‑line providers, a researcher, and an advocacy rep. The Council must meet quarterly during the first two years and convene an annual research meeting; it advises HHS on priorities and sunsets with the law. The explicit membership and meeting cadence will shape whose perspectives influence HHS decisions and when.
Data sharing and annual reporting to Congress
Directs federal agency heads to share headache‑related data with HHS at the Secretary’s request, and explicitly includes standardization and integration with non‑federal sources (EHRs, registries, surveys). HHS must use those data to produce an annual report evaluating federally funded efforts, documenting disparities, making priority recommendations (including on Medicare costs and diagnostics), and issuing an annually updated national plan. Together these sections create a statutory pipeline from data collection to public accountability, but they stop short of authorizing funding or prescribing technical interoperability standards.
Five‑year sunset
The Act terminates five years after enactment. That termination clause concentrates legislative pressure to produce deliverables quickly but limits the law’s ability to support long‑horizon research programs or sustained structural changes unless reauthorized or funded through other mechanisms.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with chronic and episodic headache disorders (including migraine and cluster headache) — the bill directs federal attention to diagnosis, new therapeutics, care pathways, stigma reduction, and targeted data collection to identify and close disparities. This could improve access, clinical guidance, and research tailored to these patients.
- Underserved and vulnerable populations (children, pregnant people, older adults, communities disproportionately affected) — the statute requires inclusive epidemiology and disparity analysis, which should surface gaps in diagnosis and care for these groups and direct program priorities to address them.
- Headache clinicians and specialized centers — the bill explicitly pushes workforce expansion and care pathway development; specialists may see increased research funding, training resources, and recognition of specialty practice needs (e.g., reimbursement or referral standards).
- Researchers in headache and pain science — the NHDI prioritizes fundamental, translational, and clinical research and integrates federal programs, which can create clearer funding priorities and cooperative research agendas.
- Patient advocacy organizations focused on headache disorders — required patient representation on the Advisory Council and mandated public awareness and stigma‑reduction activities increase advocacy influence and may expand collaboration opportunities with federal programs.
Who Bears the Cost
- HHS (and lead program offices) — HHS must design, coordinate, and update the NHDI, manage the advisory council, request and integrate cross‑agency data, and produce annual reports; these duties will require staff time and program resources that the bill does not explicitly appropriate.
- Other federal agencies with health data (NIH, CDC, VA, DOD, CMS, IHS, AHRQ, ARPA‑H) — the statute requires these agencies to share standardized data and participate in coordination; that entails IT, privacy compliance, and analytics costs, and possible reallocation of staff time.
- Health systems, EHR vendors, and registries — integration with non‑federal data sources is a statutory objective; systems may face new technical work to standardize and transmit data, and compliance officers will need to reconcile privacy/HIPAA requirements with sharing requests.
- Medicare, Medicaid, and federal payers — the bill asks for evaluations and recommendations aimed at reducing their financial burden from headache disorders; if policymakers adopt coverage changes or benefit expansions, payers could face increased short‑term costs.
- Small clinical practices and front‑line providers — the initiative’s emphasis on care pathways and data collection could introduce reporting or referral expectations that add administrative burdens for primary care and emergency clinicians.
Key Issues
The Core Tension
The central tension is between urgently elevating headache disorders through a coordinated federal initiative (which requires broad data access, interagency action, and visible short‑term deliverables) and the reality that meaningful research, workforce development, and interoperable data systems need sustained funding, multi‑year technical work, and careful privacy governance — none of which the statute itself guarantees and the five‑year sunset may truncate.
Two implementation tensions are immediate. First, the bill mandates broad, standardized data sharing across agencies and with non‑federal EHRs and registries but does not provide technical standards, funding to build interoperability, or a clear privacy framework beyond existing law.
Converting heterogeneous clinical records into usable, comparable datasets is expensive and legally complex; absent appropriations or implementation guidance, the data‑integration goals risk being aspirational.
Second, the statute demands programmatic priorities (workforce expansion, research, clinical pathways, stigma reduction) and asks the Secretary to ensure resources are "commensurate with the high disease burden," yet it contains no authorization of appropriations. That creates a structural mismatch: HHS gains new responsibilities and expectations but no guaranteed funding stream.
The five‑year sunset compounds this: many research and workforce initiatives require longer time horizons to show value, and the short statutory life may bias HHS toward quick wins rather than durable investments.
Other practical questions remain. The Advisory Council’s mix of federal and non‑federal members ensures stakeholder input but raises potential conflict‑of‑interest and governance issues (e.g., how industry‑funded researchers or advocacy groups are vetted).
The law’s broad definition of headache disorders (including long COVID and orofacial pain) benefits comprehensiveness but may diffuse program focus. Finally, the bill creates evaluative and budget review obligations for HHS; those reviews could recommend changes that shift funding across programs (including HEAL and other pain initiatives), producing distributional trade‑offs across agencies and conditions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.